Redeye interviews Oncopeptides CEO Sofia Heigis about the Q3 report, the impact of the summer period on Pepaxti sales, preparations ahead of an EC decision on third-line treatment, and the glioblastoma program.
The interview is in Swedish.
Redeye interviews Oncopeptides CEO Sofia Heigis about the Q3 report, the impact of the summer period on Pepaxti sales, preparations ahead of an EC decision on third-line treatment, and the glioblastoma program.
The interview is in Swedish.
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care